Omics Technologies for
Clinical Applications
I apply cutting-edge omics technologies, particularly high-resolution mass spectrometry and multi-omics, to unravel the biological effects of xenobiotics and drug metabolism. My work on neuropsychiatric adverse drug reactions (ADRs) in pediatric patients, with a focus on montelukast, integrates metabolomics with clinical data to identify key biomarkers for early drug toxicity detection. This research emphasizes the role of metabolic profiles in assessing drug safety and developing personalized medicine approaches, ultimately contributing to improving healthcare outcomes in complex disease contexts, such as COVID-19 and antibiotic resistance.
Drug Discovery
My research focuses on advancing drug discovery through integrative approaches that combine mass spectrometry, multi-omics, and computational biochemistry. A key component is the development of novel lead compounds inspired by natural products, such as selenium-containing derivatives of chrysin and quercetin, and C-scorpionate metal complexes for cancer therapy. These compounds are evaluated through in vitro studies and mechanistic analyses, which provide a deeper understanding of their anti-cancer properties and potential for therapeutic application. This work also extends to target identification for multi-drug resistant pathogens and other critical health conditions, offering new insights into therapeutic repurposing and personalized treatment strategies.
Mass Spectrometry and Computational Biochemistry for Health
My research integrates mass spectrometry and computational biochemistry to explore chemical-biological interactions and discover novel drug candidates. By combining experimental data with computational simulations, I investigate the mechanisms behind disease progression and therapeutic effects, with a particular emphasis on drug-receptor interactions and biotransformation pathways. This interdisciplinary approach fosters drug design and development, focusing on small molecules, immune-modulatory compounds, and biomarker identification for conditions ranging from cancer to neurodegenerative diseases, and infectious diseases like methicillin-resistant Staphylococcus aureus (MRSA).
